Status:
COMPLETED
Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Conditions:
Kidney Transplant
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
During the past 15 years, however, the superior immunosuppressive efficacy of CsA and the well-known toxicity of long-term steroid therapy have prompted trials of steroid withdrawal from renal allogra...
Detailed Description
The last 40 years have been a period of remarkable evolution of organ transplantation from nothing to a well-established form of treatment with good short-term results. These findings were achieved ma...
Eligibility Criteria
Inclusion
- Eligible kidney transplant according to standard criteria
- Recipient of first kidney transplant
- Cadaver or living-related donor
- Written informed consent
Exclusion
- Panel reactive antibodies titer \>50%
- HLA identical
- High risk of recurrence of renal disease (FSGS, vasculitis, membranous nephropathy)
- Primary and secondary hyperlipidemia
- Platelet count \<150000/microliter
- Specific contraindication to the study drug
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
April 1 2010
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00309270
Start Date
February 1 2003
End Date
April 1 2010
Last Update
May 22 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital "Ospedali Riuniti" of Bergamo
Bergamo, Italy, 24128